治疗前全身免疫炎症指数作为预测肾细胞癌患者临床结局的非侵入性生物标志物:20项研究的荟萃分析

IF 2 4区医学 Q3 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Biomarkers Pub Date : 2023-05-01 DOI:10.1080/1354750X.2023.2164906

Jun Xu, Junying Song, Zhenhua Yang, Jianguo Zhao, Jianfang Wang, Caiping Sun, Xiaoling Zhu

{"title":"治疗前全身免疫炎症指数作为预测肾细胞癌患者临床结局的非侵入性生物标志物:20项研究的荟萃分析","authors":"Jun Xu, Junying Song, Zhenhua Yang, Jianguo Zhao, Jianfang Wang, Caiping Sun, Xiaoling Zhu","doi":"10.1080/1354750X.2023.2164906","DOIUrl":null,"url":null,"abstract":"Introduction: To systematically assess the predictive significance of systemic immune-inflammation index (SII) in renal cell carcinoma (RCC).Methods: Relevant studies published before November 2022 were retrieved from public databases. Hazard ratio (HR), standardised mean difference (SMD) and relative risk (RR) were calculated to estimate associations of SII with prognosis, treatment responses and clinicopathological features.Results: Twenty studies involving 6887 patients were eligible. The meta-analysis results revealed a high SII level was associated with worse overall survival (HR: 1.45, p < 0.001), progression-free survival (HR: 1.63, p = 0.001), cancer-specific survival (HR: 1.86, p < 0.001), lower overall response rate (RR: 0.62, p = 0.003), disease control rate (RR: 0.69, p = 0.002), larger tumour size (SMD: 0.39, p = 0.001), poorer IMDC risk (RR: 7.09, p < 0.001), higher Fuhrman grade (RR: 1.54, p = 0.004), tumour stage (RR: 1.67, p = 0.045), the presence of distant metastasis (brain: RR, 2.04, p = 0.001; bone: RR, 1.33, p = 0.024) and tumour necrosis (RR: 1.57, p = 0.031). Subgroup analysis showed SII predicted OS and PFS for non-Asian, but CSS for both Asian and non-Asian populations.Conclusion: Pre-treatment SII may be a promising predictor of clinical outcomes for RCC patients.","PeriodicalId":8921,"journal":{"name":"Biomarkers","volume":"28 3","pages":"249-262"},"PeriodicalIF":2.0000,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Pre-treatment systemic immune-inflammation index as a non-invasive biomarker for predicting clinical outcomes in patients with renal cell carcinoma: a meta-analysis of 20 studies.\",\"authors\":\"Jun Xu, Junying Song, Zhenhua Yang, Jianguo Zhao, Jianfang Wang, Caiping Sun, Xiaoling Zhu\",\"doi\":\"10.1080/1354750X.2023.2164906\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction: To systematically assess the predictive significance of systemic immune-inflammation index (SII) in renal cell carcinoma (RCC).Methods: Relevant studies published before November 2022 were retrieved from public databases. Hazard ratio (HR), standardised mean difference (SMD) and relative risk (RR) were calculated to estimate associations of SII with prognosis, treatment responses and clinicopathological features.Results: Twenty studies involving 6887 patients were eligible. The meta-analysis results revealed a high SII level was associated with worse overall survival (HR: 1.45, p < 0.001), progression-free survival (HR: 1.63, p = 0.001), cancer-specific survival (HR: 1.86, p < 0.001), lower overall response rate (RR: 0.62, p = 0.003), disease control rate (RR: 0.69, p = 0.002), larger tumour size (SMD: 0.39, p = 0.001), poorer IMDC risk (RR: 7.09, p < 0.001), higher Fuhrman grade (RR: 1.54, p = 0.004), tumour stage (RR: 1.67, p = 0.045), the presence of distant metastasis (brain: RR, 2.04, p = 0.001; bone: RR, 1.33, p = 0.024) and tumour necrosis (RR: 1.57, p = 0.031). Subgroup analysis showed SII predicted OS and PFS for non-Asian, but CSS for both Asian and non-Asian populations.Conclusion: Pre-treatment SII may be a promising predictor of clinical outcomes for RCC patients.\",\"PeriodicalId\":8921,\"journal\":{\"name\":\"Biomarkers\",\"volume\":\"28 3\",\"pages\":\"249-262\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2023-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biomarkers\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/1354750X.2023.2164906\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"BIOTECHNOLOGY & APPLIED MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1354750X.2023.2164906","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 1

摘要

目的:系统评价全身免疫炎症指数(SII)对肾癌(RCC)的预测意义。方法:从公共数据库检索2022年11月前发表的相关研究。计算危险比(HR)、标准化平均差(SMD)和相对危险度(RR)来估计SII与预后、治疗反应和临床病理特征的相关性。结果:20项研究纳入6887例患者。荟萃分析结果显示，高SII水平与较差的总生存期相关(HR: 1.45, p)。结论:治疗前SII可能是RCC患者临床预后的一个有希望的预测因子。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Pre-treatment systemic immune-inflammation index as a non-invasive biomarker for predicting clinical outcomes in patients with renal cell carcinoma: a meta-analysis of 20 studies.

Introduction: To systematically assess the predictive significance of systemic immune-inflammation index (SII) in renal cell carcinoma (RCC).

Methods: Relevant studies published before November 2022 were retrieved from public databases. Hazard ratio (HR), standardised mean difference (SMD) and relative risk (RR) were calculated to estimate associations of SII with prognosis, treatment responses and clinicopathological features.

Results: Twenty studies involving 6887 patients were eligible. The meta-analysis results revealed a high SII level was associated with worse overall survival (HR: 1.45, p < 0.001), progression-free survival (HR: 1.63, p = 0.001), cancer-specific survival (HR: 1.86, p < 0.001), lower overall response rate (RR: 0.62, p = 0.003), disease control rate (RR: 0.69, p = 0.002), larger tumour size (SMD: 0.39, p = 0.001), poorer IMDC risk (RR: 7.09, p < 0.001), higher Fuhrman grade (RR: 1.54, p = 0.004), tumour stage (RR: 1.67, p = 0.045), the presence of distant metastasis (brain: RR, 2.04, p = 0.001; bone: RR, 1.33, p = 0.024) and tumour necrosis (RR: 1.57, p = 0.031). Subgroup analysis showed SII predicted OS and PFS for non-Asian, but CSS for both Asian and non-Asian populations.

Conclusion: Pre-treatment SII may be a promising predictor of clinical outcomes for RCC patients.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Biomarkers 医学-毒理学

CiteScore

5.00

自引率

3.80%

发文量

140

审稿时长

3 months

期刊介绍： The journal Biomarkers brings together all aspects of the rapidly growing field of biomarker research, encompassing their various uses and applications in one essential source. Biomarkers provides a vital forum for the exchange of ideas and concepts in all areas of biomarker research. High quality papers in four main areas are accepted and manuscripts describing novel biomarkers and their subsequent validation are especially encouraged: • Biomarkers of disease • Biomarkers of exposure • Biomarkers of response • Biomarkers of susceptibility Manuscripts can describe biomarkers measured in humans or other animals in vivo or in vitro. Biomarkers will consider publishing negative data from studies of biomarkers of susceptibility in human populations.